Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CASI Pharmaceuticals (CASI) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to 320.65%.

  • Pharmaceuticals' EBITDA Margin fell 1376600.0% to 320.65% in Q2 2025 from the same period last year, while for Jun 2025 it was 155.9%, marking a year-over-year decrease of 3611300.0%. This contributed to the annual value of 139.58% for FY2024, which is 587700.0% up from last year.
  • According to the latest figures from Q2 2025, Pharmaceuticals' EBITDA Margin is 320.65%, which was down 1376600.0% from 179.55% recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' EBITDA Margin peaked at 725.84% during Q4 2023, and registered a low of 320.65% during Q2 2025.
  • In the last 4 years, Pharmaceuticals' EBITDA Margin had a median value of 85.06% in 2022 and averaged 39.86%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 3441600bps in 2024, then tumbled by -4562300bps in 2025.
  • Quarter analysis of 4 years shows Pharmaceuticals' EBITDA Margin stood at 702.86% in 2022, then increased by 3bps to 725.84% in 2023, then plummeted by -125bps to 182.99% in 2024, then crashed by -75bps to 320.65% in 2025.
  • Its last three reported values are 320.65% in Q2 2025, 179.55% for Q1 2025, and 182.99% during Q2 2024.